I agree. Most of the available shares have been eaten up and will continue to be eaten up. This is going up for some time to come. I think Biomedreports' short term price target of $.40 is very realistic given the alignment of events.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.